Exelixis Q2 2022 revenue $419.4M, cabozantinib net product revenue $347M, GAAP EPS $0.22

EXELIXIS, INC.

2022-Q2 EPS reported $0.43 revenue$775,407,000

Total revenues $419.4M, up from $385.2M in Q2 2021; cabozantinib franchise net product revenue $347.0M, up 22% YoY.
GAAP net income $70.7M ($0.22 diluted EPS) vs $96.1M ($0.30) in Q2 2021; non-GAAP EPS $0.28.
Cash and investments $2.0B at June 30, 2022, up from $1.9B at year-end 2021.
Positive PFS data for COSMIC-313; initiated STELLAR-303 phase 3 for XL092 and phase 1 for XL114.
Signed business development agreements with BioInvent and Ryvu Therapeutics to expand biologics capabilities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.